The pursuit of optimal semaglutide dosing in type 2 diabetes continues
- PMID: 37385277
- DOI: 10.1016/S0140-6736(23)01233-3
The pursuit of optimal semaglutide dosing in type 2 diabetes continues
Conflict of interest statement
CHS holds grants from the National Association of Chain Drug Stores Foundation and American Association of Colleges of Pharmacy. CHS has received honoraria from Pharmacy Times Continuing Education (PTCE) through grants that PTCE received from Abbott, but her work for PTCE was not reviewed or influenced by Abbott. AYH declares no competing interests.
Comment on
-
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.Lancet. 2023 Aug 26;402(10403):693-704. doi: 10.1016/S0140-6736(23)01127-3. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385279 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical